Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methimazole
Drug ID BADD_D01414
Description Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339] On a weight basis, methimazole is 10 times more potent than the other major antithyroid thionamide used in North America, [propylthiouracil],[L8339] and is the active metabolite of the pro-drug [carbimazole], which is an antithyroid medication used in the United Kingdom and parts of the former British Commonwealth.[A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred in pregnancy due to a perceived lower risk of teratogenic effects. Despite documented teratogenic effects in its published labels,[L8336,L8339] the true teratogenicity of methimazole appears to be unclear[A184643,A184757,A184763] and its place in therapy may change in the future.
Indications and Usage For the treatment of hyperthyroidism, goiter, Graves disease and psoriasis.
Marketing Status Prescription; Discontinued
ATC Code H03BB02
DrugBank ID DB00763
KEGG ID D00401
MeSH ID D008713
PubChem ID 1349907
TTD Drug ID D0S4BR
NDC Product Code 68071-5197; 38779-0360; 60429-380; 63629-2027; 63629-8347; 64980-260; 51927-1943; 71335-0883; 63629-9250; 63629-2026; 63629-9137; 50090-3334; 60687-357; 23155-070; 60429-381; 49884-640; 70518-1506; 63629-9251; 50090-2366; 51552-0822; 62991-1515; 70518-1475; 62135-206; 60687-370; 63629-2225; 66219-0253; 63629-9249; 0185-0205; 0185-0210; 54382-112; 23155-071; 63629-2224; 49884-641; 62135-205; 49452-4573; 64980-261; 63629-6408
Synonyms Methimazole | 1-Methyl-2-mercaptoimidazole | 1 Methyl 2 mercaptoimidazole | Merkazolil | Tiamazol | Thiamazole | Thimazol | Mercasolyl | Mercazolyl | Methymazol | Methylmercaptoimidazole | Mercazol | Mercazole | Metisol | Metizol | Tapazole | Tirodril | Strumazol | Thiamazol Henning | Henning, Thiamazol | Thiamazol Hexal | Hexal, Thiamazol | Thyrozol | Favistan | Methizol
Chemical Information
Molecular Formula C4H6N2S
CAS Registry Number 60-56-0
SMILES CN1C=CNC1=S
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Insulin autoimmune syndromeHLA class II histocompatibility antigen, DRB1 beta chainP01911Not Available8064238; 11751969; 7604034; 9119530; 15711804; 10233671; 7679413; 7519208; 11290778
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Congenital nail disorder23.02.05.022; 03.05.02.0010.001083%Not Available
Maternal drugs affecting foetus18.03.03.009; 12.03.03.0060.002166%Not Available
Neonatal respiratory distress syndrome22.11.02.010; 18.04.10.0030.001083%Not Available
Osteomyelitis acute15.02.05.008; 11.01.01.0080.001083%Not Available
Plasmacytosis01.02.01.0170.001083%Not Available
Thyrotoxic periodic paralysis05.02.02.005; 17.01.04.021; 14.11.01.0450.001083%Not Available
Anti-neutrophil cytoplasmic antibody positive vasculitis24.05.02.016; 10.02.02.0230.005414%Not Available
Autoimmune neutropenia10.04.01.010; 01.02.03.0130.001624%Not Available
Periorbital cellulitis11.02.01.045; 06.04.11.0040.001083%Not Available
Microscopic polyangiitis20.05.01.017; 24.05.02.021; 10.02.02.0250.001083%Not Available
Vitello-intestinal duct remnant03.04.04.007; 07.11.04.0120.002166%Not Available
The 6th Page    First    Pre   6    Total 6 Pages